BC Cancer, Vancouver, British Columbia, Canada.
The University of British Columbia, Vancouver, British Columbia, Canada.
Cancer Res Commun. 2023 Apr 6;3(4):548-557. doi: 10.1158/2767-9764.CRC-22-0385. eCollection 2023 Apr.
Preoperative radiotherapy for early-stage rectal cancer has risks and benefits that may impact treatment choice in young patients. We reviewed radiotherapy use and outcomes for rectal cancer by age. Patients with early-stage rectal cancer in the Canadian province of British Columbia from 2002 to 2016 were identified ( = 6,232). Baseline characteristics, treatment response, overall survival (OS), disease-free survival (DFS), disease-specific survival (DSS), and locoregional recurrence rate (LRR) were compared between patients <50 (early-onset; = 532) and ≥50 years old (average-onset; = 5,700). Early-onset patients were more likely to receive preoperative chemoradiotherapy than short-course radiotherapy [OR, 2.20; 95% confidence interval (CI), 1.67-2.89; < 0.0001], but also had higher nodal ( = 0.00096) and overall clinical staging ( = 0.033). Cancer downstaging and pathologic complete response rates were similar in those receiving neoadjuvant chemoradiotherapy by age. Early-onset and average-onset patients had similar DSS ( = 0.91) and DFS ( 0.27) in multivariate analysis unless non-colorectal deaths, which were higher in older patients, were censored in the DFS model (HR, 1.30; 95% CI, 1.01-1.68; = 0.042). LRR also did not differ between age groups ( = 0.88). Outcomes did not differ based on radiotherapy type. Young patients with rectal cancer are more likely to present with higher staging and receive long-course chemoradiotherapy. DSS did not differ by age group; however, young patients had worse DFS when we censored competing risks of death in older patients.
This population-based study suggests younger patients are more likely to receive chemoradiotherapy, potentially due to higher stage at diagnosis, and response is comparable by age.
探讨早期直肠癌术前放疗的风险和获益,这些因素可能会影响年轻患者的治疗选择。我们通过年龄回顾了直肠癌放疗的应用和结果。
本研究回顾性分析了 2002 年至 2016 年加拿大不列颠哥伦比亚省的早期直肠癌患者(n=6232)。比较了<50 岁(早发组,n=532)和≥50 岁(平均发病年龄组,n=5700)患者的基线特征、治疗反应、总生存期(OS)、无病生存期(DFS)、疾病特异性生存期(DSS)和局部区域复发率(LRR)。早发组患者接受术前放化疗的比例高于短程放疗(OR,2.20;95%CI,1.67-2.89;P<0.0001),但淋巴结(P=0.00096)和总体临床分期(P=0.033)更高。年龄相同时,接受新辅助放化疗的患者降期和病理完全缓解率相似。多因素分析显示,早发和平均发病年龄组患者的 DSS(P=0.91)和 DFS(P=0.27)相似,除非在 DFS 模型中排除了老年患者更高的非结直肠癌死亡率(HR,1.30;95%CI,1.01-1.68;P=0.042)。LRR 两组间无差异(P=0.88)。不同放疗类型之间结局无差异。年轻直肠癌患者更有可能表现出更高的分期,接受长程放化疗。年龄组之间 DSS 无差异;然而,当我们排除老年患者死亡的竞争风险时,年轻患者的 DFS 更差。
本基于人群的研究表明,年轻患者更有可能接受放化疗,可能是由于诊断时的分期更高,且年龄相同时的治疗反应无差异。